Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

A randomized, double-blind, placebo-controlled trial of a novel BTK inhibitor (rilzabrutinib) in patients with sickle cell disease (SCD) aged 10–65 years: LIBRA Study

Kenneth Ataga, Biree Andemariam, David Rees, Hailing Guo, Ahmed Daak

Blood (2025) 146 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2025-2975

Published: 2025

Journal Articles

Explainable AI-based prediction of chronic kidney disease as a long-term outcome of sickle cell disease in a large, multi-site observational data cohort

Biree Andemariam, Kathleen Torres, Joseph Romano

Blood (2025) 146 (Supplement 1): 2967.

https://doi.org/10.1182/blood-2025-2967

Published: 2025

Journal Articles

Bridging the gap: Global caregiver perspectives on awareness, motivators, and barriers to clinical trial participation in sickle cell disease

John James, Johnny Mahlangu, Raffaella Colombatti, Cassandra Trimnell, Darren Fleetwood, Emma Tan, Biree Andemariam

Blood (2025) 146 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2025-2952

Published: 2025

Journal Articles

Qualitative interviews exploring the patient experience of fatigue in individuals with sickle cell disease (SCD), thalassemia, and pyruvate kinase (PK) deficiency

Blood (2025) 146 (Supplement 1): 7971.

https://doi.org/10.1182/blood-2025-7971

Published: 2025

Journal Articles

Trust and relationships between people with sickle cell disease and healthcare professionals: Regional comparisons from the listen survey

Biree Andemariam, Shashidhar Rao, Rohan Kolla, Emma Tan, Johnny Mahlangu

Blood (2025) 146 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2025-2669

Published: 2025

Journal Articles

Sickle cell disease trials redefined: Toward unified clinical endpoints through international consensus

Mohamed Yassin, Nirmish Shah, Andrew Campbell, Salam Al-Kindi, Wally Smith, Charles Jonassaint, Miguel Abboud, Raffaella Colombatti, Dipty Jain, Halima Bello-Manga, Mariane de Montalembert, Ana Silva-Pinto, Steven Okoli, Abdelaziz Fahem, Biree Andemariam

Blood (2025) 146 (Supplement 1): 1166.

https://doi.org/10.1182/blood-2025-1166

Published: 2025

Journal Articles

A phase 2 open-label study of epeleuton in patients with sickle cell disease

Biree Andemariam, Vivien Sheehan, Fuad El Rassi, Moayed Hamza, Kirsty Kelly, John Climax

Blood (2025) 146 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2025-4754

Published: 2025

Journal Articles

Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services – the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Sophia Jan, Caren Steinway, Tanisha Belton, Justine Shults, Laura Bennett, Heather Griffis, Banu Aygun, Abena Appiah-Kubi, Nataly Apollonsky, Donna Boruchov, Omar Niss, Lisa A. Schwartz, Lori E. Crosby, Lamia Barakat, Biree Andemariam, David Rubin, Kim Smith-Whitley

Blood (2024) 144 (Supplement 1): 1066.

https://doi.org/10.1182/blood-2024-205273

Published: 2024

Journal Articles

Clinical Complications and Healthcare Resource Utilization in Medicaid and Commercially Insured Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions

Chuka Udeze, Michelle Jerry, Kristin Evans, Nanxin Li, Siddharth Jain, Biree Andemariam

Blood (2024) 144 (Supplement 1): 7661.

https://doi.org/10.1182/blood-2024-204008

Published: 2024

Journal Articles

Adherence, Clinical and Economic Outcomes in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Treated with L-Glutamine, Voxelotor, or Crizanlizumab Covered By Medicaid and Commercial Insurance in the United States

Chuka Udeze, Michelle Jerry, Kristin Evans, Nanxin Li, Siddharth Jain, Biree Andemariam

Blood (2024) 144 (Supplement 1): 7660.

https://doi.org/10.1182/blood-2024-203628

Published: 2024

Journal Articles

Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

Sophia Delicou, Fuad El Rassi, Biree Andemariam, Miguel R. Abboud, Julie Kanter, Marilyn J. Telen, Jessie Githanga, Adlette Inati, Ibrahim Idris, Sunil Navani, Eric Wu, Andrew Eisenberger

Blood (2024) 144 (Supplement 1): 179.

https://doi.org/10.1182/blood-2024-204962

Published: 2024

Journal Articles

Motivators and Barriers for People with Sickle Cell Disease Participating in Clinical Trials: United States Findings from the Listen Survey

Biree Andemariam, Adam Wufsus, Erik Hecht, Cassandra Trimnell

Blood (2024) 144 (Supplement 1): 1139.

https://doi.org/10.1182/blood-2024-194253

Published: 2024

Journal Articles

Characterizing People with Sickle Cell Disease Who Share Attitudes Regarding Clinical Trial Participation: Findings from the Global LISTEN Survey

Johnny Mahlangu, John James, Biree Andemariam, John Waller, Samar Al-Behaisi, Gareth Morrell, Raffaella Colombatti, Cassandra Trimnell

Blood (2024) 144 (Supplement 1): 1135.

https://doi.org/10.1182/blood-2024-200550

Published: 2024

Journal Articles

Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study

Jayanne Forrest, Caren Steinway, Eelia Shaw, Sophia Jan, Banu Aygun, Abena Appiah-Kubi, Nataly Apollonsky, Donna Boruchov, Omar Niss, Biree Andemariam, Kim Smith-Whitley, Symme Trachtenberg, Tanisha Belton

Blood (2024) 144 (Supplement 1): 617.

https://doi.org/10.1182/blood-2024-206036

Published: 2024

Journal Articles

How People with Sickle Cell Disease Rate Motivators is Associated with the Likelihood of Wanting to Participate in a Clinical Trial: Findings from the Global LISTEN Survey

Biree Andemariam, Johnny Mahlangu, Raffaella Colombatti, John Waller, Samar Al-Behaisi, Gareth Morrell, John James

Blood (2024) 144 (Supplement 1): 1137.

https://doi.org/10.1182/blood-2024-200009

Published: 2024

Journal Articles

Primary Analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism

Blood (2023) 142 (Supplement 1): 146.

https://doi.org/10.1182/blood-2023-179042

Published: 2023

Journal Articles

Motivators and Barriers for People with Sickle Cell Disease Participating in Clinical Trials: Global Findings from the LISTEN Survey

John James, Biree Andemariam, Johnny Mahlangu, Raffaella Colombatti, John Waller, Samar Al-Behaisi, Adam Wufsus, Gareth Morrell, Cassandra Trimnell

Blood (2023) 142 (Supplement 1): 2498.

https://doi.org/10.1182/blood-2023-181910

Published: 2023

Journal Articles

Advancing Care of Patients with Sickle Cell Disease through a Transformative Quality Improvement Initiative

Biree Andemariam, Shelby Sullivan, Jeffrey Carter, Cherilyn Heggen

Blood (2023) 142 (Supplement 1): 7224.

https://doi.org/10.1182/blood-2023-173457

Published: 2023

Journal Articles

Cross-Community Collaboration and Data Collection to Optimize Patient Care in Hemolytic Anemias

Blood (2023) 142 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2023-181632

Published: 2023

Journal Articles

Real-World Experience of Individuals with Sickle Cell Disease Treated with Voxelotor: Initial Report from the Multicenter, Prospective Prospect Study

Biree Andemariam, Henny H. Billett, William B Ershler, Shayla Bergmann, Vishwas S. Sakhalkar, Alicia Chang, Payal Desai, Nirmish Shah, Sharon Pennington, Robin E. Miller, Laura M. Decastro, Michelle Xu, Brooke Hayward, Ching-Ray Yu, Darla K. Liles

Blood (2023) 142 (Supplement 1): 2499.

https://doi.org/10.1182/blood-2023-188746

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A randomized, double-blind, placebo-controlled trial of a novel BTK inhibitor (rilzabrutinib) in patients with sickle cell disease (SCD) aged 10–65 years: LIBRA Study

Explainable AI-based prediction of chronic kidney disease as a long-term outcome of sickle cell disease in a large, multi-site observational data cohort

Bridging the gap: Global caregiver perspectives on awareness, motivators, and barriers to clinical trial participation in sickle cell disease

Qualitative interviews exploring the patient experience of fatigue in individuals with sickle cell disease (SCD), thalassemia, and pyruvate kinase (PK) deficiency

Trust and relationships between people with sickle cell disease and healthcare professionals: Regional comparisons from the listen survey

Sickle cell disease trials redefined: Toward unified clinical endpoints through international consensus

A phase 2 open-label study of epeleuton in patients with sickle cell disease

Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services – the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Clinical Complications and Healthcare Resource Utilization in Medicaid and Commercially Insured Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions

Adherence, Clinical and Economic Outcomes in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Treated with L-Glutamine, Voxelotor, or Crizanlizumab Covered By Medicaid and Commercial Insurance in the United States

Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

Motivators and Barriers for People with Sickle Cell Disease Participating in Clinical Trials: United States Findings from the Listen Survey

Characterizing People with Sickle Cell Disease Who Share Attitudes Regarding Clinical Trial Participation: Findings from the Global LISTEN Survey

Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study

How People with Sickle Cell Disease Rate Motivators is Associated with the Likelihood of Wanting to Participate in a Clinical Trial: Findings from the Global LISTEN Survey

Primary Analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism

Motivators and Barriers for People with Sickle Cell Disease Participating in Clinical Trials: Global Findings from the LISTEN Survey

Advancing Care of Patients with Sickle Cell Disease through a Transformative Quality Improvement Initiative

Cross-Community Collaboration and Data Collection to Optimize Patient Care in Hemolytic Anemias

Real-World Experience of Individuals with Sickle Cell Disease Treated with Voxelotor: Initial Report from the Multicenter, Prospective Prospect Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only